Celgene Offers High Growth At An Inexpensive Price

Six of Celgene's (CELG) clinical trials were put on hold on Thursday, but the company's growth will remain outstanding for the coming years. The strong growth outlook, a deep pipeline and a valuation that is not very high make Celgene attractive, I believe.

Merck's (MRK) Keytruda has led to problems in a drug trial where the drug was tested for the treatment of multiple myelomas in combination with immunomodulatory agents, which has made the FDA put a partial or full clinical hold on a couple of other clinical trials as well, including six of Celgene's trials under its Fusion program.


It's on us. Share your news here.

Submit your stories and articles to citybizlist today.